NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
An extracranial-to-intracranial (EC-IC) revascularization is the most widely used treatment
to improve cerebral perfusion in patients with moyamoya disease (MMD), and it has been shown
to reduce the risk of subsequent stroke and neurological deficit. However, perioperative
changes in cerebral hemodynamics can induce fluctuations in cerebral perfusion that may lead
to transient or irreversible neurological deficits. Our preliminary single-center study
suggests that postoperative intravenous administration of dl-3-n-butylphthalide (NBP) may
alleviate perioperative neurological deficits and improve the neurological outcomes after
EC-IC revascularization for MMD. This is a multicenter, randomized, double-blind,
single-controlled, add-on to standard of care study of NBP in patients with MMD of high risk
for ischemic cerebrovascular events after EC-IC revascularization surgery.